184 related articles for article (PubMed ID: 32582543)
21. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
22. Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing.
Trabucco SE; Sokol ES; Maund SL; Moore JA; Frampton GM; Albacker LA; Oestergaard MZ; Venstrom J; Sehn LH; Bolen CR
Future Oncol; 2021 Nov; 17(31):4171-4183. PubMed ID: 34313135
[TBL] [Abstract][Full Text] [Related]
23. The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms.
Hwang HS; Yoon DH; Hong JY; Park CS; Lee YS; Ko YH; Kim SJ; Kim WS; Suh C; Huh J
Ann Hematol; 2018 Dec; 97(12):2363-2372. PubMed ID: 30069703
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature.
Lee J; Hue SS; Ko SQ; Tan SY; Liu X; Girard LP; Chan EHL; De Mel S; Jeyasekharan A; Chee YL; Koh LP; Poon LM
Expert Rev Hematol; 2019 Dec; 12(12):1095-1105. PubMed ID: 31592693
[No Abstract] [Full Text] [Related]
25. Utility of reverse transcriptase - Multiplex ligation-dependant probe amplification (RT-MLPA) in the molecular classification of Diffuse Large B cell lymphoma (DLBCL) by cell-of-origin (COO).
Dcunha N; Sakhti D; Sigamani E; Chandramohan J; Korula A; George B; Manipadam MT; Pai R
Indian J Pathol Microbiol; 2023; 66(4):714-719. PubMed ID: 38084521
[TBL] [Abstract][Full Text] [Related]
26. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma.
Roberts RA; Sabalos CM; LeBlanc ML; Martel RR; Frutiger YM; Unger JM; Botros IW; Rounseville MP; Seligmann BE; Miller TP; Grogan TM; Rimsza LM
Lab Invest; 2007 Oct; 87(10):979-97. PubMed ID: 17700562
[TBL] [Abstract][Full Text] [Related]
27. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.
Scott DW; Wright GW; Williams PM; Lih CJ; Walsh W; Jaffe ES; Rosenwald A; Campo E; Chan WC; Connors JM; Smeland EB; Mottok A; Braziel RM; Ott G; Delabie J; Tubbs RR; Cook JR; Weisenburger DD; Greiner TC; Glinsmann-Gibson BJ; Fu K; Staudt LM; Gascoyne RD; Rimsza LM
Blood; 2014 Feb; 123(8):1214-7. PubMed ID: 24398326
[TBL] [Abstract][Full Text] [Related]
28. Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL.
Perfecto-Avalos Y; Garcia-Gonzalez A; Hernandez-Reynoso A; Sánchez-Ante G; Ortiz-Hidalgo C; Scott SP; Fuentes-Aguilar RQ; Diaz-Dominguez R; León-Martínez G; Velasco-Vales V; Cárdenas-Escudero MA; Hernández-Hernández JA; Santos A; Borbolla-Escoboza JR; Villela L
J Transl Med; 2019 Jun; 17(1):198. PubMed ID: 31185999
[TBL] [Abstract][Full Text] [Related]
29. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.
Montalbán C; Díaz-López A; Martín A; Baile M; Sanchez JM; Sancho JM; García O; Novelli S; Monter-Rovira A; Salar A; Bastos M; Gutiérrez A; Bento L; Córdoba R; Arquero T; González de Villambrosia S; Barranco G; De Oña R; López Guillermo A; Rodriguez Salazar MJ; Domínguez JF; Fernández R; Queizan JA; Rodríguez J; Abraira V; García JF;
Br J Haematol; 2018 Aug; 182(4):534-541. PubMed ID: 29978453
[TBL] [Abstract][Full Text] [Related]
30. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.
Xu-Monette ZY; Zhang H; Zhu F; Tzankov A; Bhagat G; Visco C; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Hagemeister FB; Shahbaba B; De Dios I; Zhang H; Li Y; Xu B; Albitar M; Young KH
Blood Adv; 2020 Jul; 4(14):3391-3404. PubMed ID: 32722783
[TBL] [Abstract][Full Text] [Related]
31. Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma.
Plaça JR; Diepstra A; Los T; Mendeville M; Seitz A; Lugtenburg PJ; Zijlstra J; Lam K; da Silva WA; Ylstra B; de Jong D; van den Berg A; Nijland M
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267654
[TBL] [Abstract][Full Text] [Related]
32. Expression of programmed cell death ligand-1 protein in germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Asrini R; Ham MF; Asmarinah A; Harahap AS; Hardjolukito ESR
Mol Clin Oncol; 2022 Feb; 16(2):42. PubMed ID: 35003740
[TBL] [Abstract][Full Text] [Related]
33. Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series.
Zamò A; Gerhard-Hartmann E; Ott G; Anagnostopoulos I; Scott DW; Rosenwald A; Rauert-Wunderlich H
Virchows Arch; 2022 Dec; 481(6):935-943. PubMed ID: 36219238
[TBL] [Abstract][Full Text] [Related]
34. Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance.
Ahmed S; Glover P; Taylor J; Sha C; Care MA; Tooze R; Davies A; Westhead DR; Johnson PWM; Burton C; Barrans SL
Br J Haematol; 2021 Feb; 192(3):599-604. PubMed ID: 33249557
[TBL] [Abstract][Full Text] [Related]
35. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.
Li X; Xu-Monette ZY; Yi S; Dabaja BS; Manyam GC; Westin J; Fowler N; Miranda RN; Zhang M; Ferry JA; Medeiros LJ; Harris NL; Young KH
Am J Surg Pathol; 2017 Oct; 41(10):1309-1321. PubMed ID: 28817403
[TBL] [Abstract][Full Text] [Related]
36. Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland.
Reber R; Banz Y; Garamvölgyi E; Perren A; Novak U
Swiss Med Wkly; 2013; 143():w13748. PubMed ID: 23740154
[TBL] [Abstract][Full Text] [Related]
37. Clinical pathology of primary central nervous system lymphoma in HIV-positive patients-a 41 Chinese patients retrospective study.
Chen J; Sun L; Dai Y; Zhang L; Yang K; Han X; Ding X; Gao H; Zhou X; Wang P
Ann Diagn Pathol; 2023 Apr; 63():152108. PubMed ID: 36638601
[TBL] [Abstract][Full Text] [Related]
38. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.
Ciavarella S; Vegliante MC; Fabbri M; De Summa S; Melle F; Motta G; De Iuliis V; Opinto G; Enjuanes A; Rega S; Gulino A; Agostinelli C; Scattone A; Tommasi S; Mangia A; Mele F; Simone G; Zito AF; Ingravallo G; Vitolo U; Chiappella A; Tarella C; Gianni AM; Rambaldi A; Zinzani PL; Casadei B; Derenzini E; Loseto G; Pileri A; Tabanelli V; Fiori S; Rivas-Delgado A; López-Guillermo A; Venesio T; Sapino A; Campo E; Tripodo C; Guarini A; Pileri SA
Ann Oncol; 2018 Dec; 29(12):2363-2370. PubMed ID: 30307529
[TBL] [Abstract][Full Text] [Related]
39. Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study.
Urata T; Naoi Y; Jiang A; Boyle M; Sunami K; Imai T; Nawa Y; Hiramatsu Y; Yamamoto K; Fujii S; Yoshida I; Yano T; Chijimatsu R; Murakami H; Ikeuchi K; Kobayashi H; Tani K; Ujiie H; Inoue H; Tomida S; Yamamoto A; Kondo T; Fujiwara H; Asada N; Nishimori H; Fujii K; Fujii N; Matsuoka KI; Sawada K; Momose S; Tamaru JI; Nishikori A; Sato Y; Yoshino T; Maeda Y; Scott DW; Ennishi D
Blood Adv; 2023 Dec; 7(24):7459-7470. PubMed ID: 37552496
[TBL] [Abstract][Full Text] [Related]
40. Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma.
Hill BT; Sweetenham J
Leuk Lymphoma; 2012 May; 53(5):763-9. PubMed ID: 21992676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
